Disease and Acetylation Polymorphism

Clinical Pharmacokinetics

Volumn 2, Issue 3, 1977, Pages 182-197

  Lunde, Per Knut M ^a   Frislid, K ^a   Hansleen, V ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; DAPSONE; HYDRALAZINE; ISONIAZID; LIVER ENZYME; NITRAZEPAM; PHENELZINE; PROCAINAMIDE; SULFADIMIDINE; SULFAPYRIDINE;

DRUG ACETYLATION; DRUG COMPARISON; DRUG METABOLISM; HUMAN; KIDNEY FAILURE; LUPUS ERYTHEMATOSUS; NORMAL HUMAN; PHARMACOKINETICS; PHENOTYPE; RACE; THEORETICAL STUDY;

ACETYLATION; CHEMISTRY, ORGANIC; DAPSONE; DISEASE; HUMAN; HYDRALAZINE; ISONIAZID; KINETICS; NITRAZEPAM; PHARMACEUTICAL PREPARATIONS; PHENELZINE; PHENOTYPE; POLYMORPHISM (GENETICS); PROCAINAMIDE; SULFONAMIDES;

EID: 0017656270     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-197702030-00003     Document Type: Article

References (99)

1. Drug-induced antinuclear antibodies and lupus syndromes
2. Isoniazid acetylation rate and development of antinuclear antibodies upon isoniazid treatment
3. Comparison between the behaviour of eskimoes and non-eskimoes to the administration of isoniazid
4. Rapid gas chromatographic measurement of plasma procainamide concentration
5. Induction of tryptophan oxygenase by dexamethasone in isolated hepatocytes
6. Determination of isoniazid and metabolites in biological fluids
7. Pharmacokinetics of isoniazid and some metabolites in man
8. Enzymatische Inaktiverung von Isonicotinsaure-hydrazid in menschlichen und tierischen Organismus
9. Acetylator phenotype and the clinical pharmacology of slow release procainamide
10. Pharmaceutical and pharmacokinetic principles in the formulation of a sustained-release procainamide tablet
11. Clinical pharmacokinetics of sulphasalazine
12. Acetylation polymorphism of sulphapyridine in patients with ulcerative colitis and Crohns disease. Clin. Pharmacol
13. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype
14. Antinuclear antibodies during procainamide treatment and during acetylation
15. Peripheral neuritis due to isoniazid
16. N-acetylprocainamide: An active metabolite of procainamide
17. Pharmacokinetics of isoniazid metabolism in man
18. Acetylator phenotyping of tuberculosis patients using matrix isoniazid or sulphadimidine and its prognostic significance for treatment with several intermittent isoniazid-containing regimens
19. Dapsone acetylation and the treatment of leprosy
20. Dapsone acetylation in dermatitis herpetiformis
21. Antiarrhythmic potency of N-acetylprocainamide
22. Pharmacogenetique
23. Conjoint clinic on drugs and genes
24. Genetic variations in acetylation of isoniazid and other drugs
25. An improved and simplified method of detecting the acetylator phenotype
26. The influence of acetylator phenotype on the effects of treating depression with phenelzine
27. Genetic control of isoniazid metabolism in man
28. Human acetylation polymorphism
29. Determination of acetylator status in uremia. Brit. J. Clin
30. Comparison of the acetylation of procainamide and sulfadimidine in man
31. Fluorometric or gas liquid chromatographic determination of procainamide
32. Acetylator phenotype minimal maintenance dose and haemolytic effect of dapsone in dermatitis herpetiformis
33. Rate of inactivation of isoniazid in South-Indian patients with pulmonary tuberculosis
34. The polymorphic acetylation of dapsone in man
35. Acetylation of procainamide in man and its relationship to isonicotinic acid hydrazide acetylation phenotype
36. Acetylator phenotype in sulphonamide resistant falciparum malaria
37. Clinical pharmacokinetics
38. Reticuloendothelial cells as the site of sulphanilamide acetylation in the rabbit
39. Immune responses to hydralazine and nuclear antigens in hydralazine-induced lupus erythematosus
40. Inactivation of isoniazid (INH) in Swedish tuberculous patients before and during treatment with para-aminosalicylic acid (PAS)
41. Maintenance therapy with a new retard tablet preparation of procainamide
42. The frequency of isoniazid acetylase enzyme deficiency among Egyptians
43. Human acetylation polymorphism in Polynesians
44. Effects of long-time treatment with procainamide
45. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis
46. Hydralazine-induced lupus erythematosus-like syndrome
47. Inactivation of isoniazid by Canadian eskimoes and indians
48. Comparative blood levels and metabolism of INH and an INH-matrix preparation in fast and slow inactivators
49. Partial purification and properties of the isoniazid transacetylase in human liver. Its relationship to the acetylation of p-aminosalicylic acid
50. A clinical study of isoniazid inactivation
51. Acetylation phenotype and the antihypertensive response to hydralazine
52. Acetylator status and response to phenelzine in depressed patients
53. Polymorphic acetylation of nitrazepam
54. Polymorphic acetylation of procainamide in healthy subjects
55. Acetylation of procainamide in man studied with a new gas chromatographic method
56. Hydralazine
57. Procainamide dosage schedules, plasmaconcentrations and clinical effects
58. Diphenyl-hydantoin intoxication. A complication of isoniazid therapy
59. Isoniazid and pseudocholinesterase polymorphism
60. Madras study of supervised once-weekly chemotherapy
61. Metabolic activation: Biochemical basis for many drug-induced liver injuries
62. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydralazine metabolites
63. Isoniazid liver injury: Clinical spectrum, pathology and probable pathogenesis
64. Clinical applications of antibiotic and chemotherapeutic agents
65. Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis
66. Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms on hypertensive patients treated with hydralazine
67. The relationship between the capacities of human subjects to acetylate isoniazid, sulphanilamid and sulphamethazin
68. The disposition of the antileprotic drug dapsone in Philippine subjects
69. Polymorphic acetylation of the antibacterials sulphamethazine and dapsone, in South Indian subjects
70. Dapsone acetylation in man. Another example of polymorphic acetylation
71. Metabolic disposition of dapsone in patients with dapsone-resistant leprosy
72. Hydralazine elimination in man
73. Polymorphic acetylation of procainamide in man
74. The acetylator phenotype of patients with systemic lupus erythematosus
75. Induction of drug metabolizing enzyme system in the liver
76. Absorption, metabolism and excretion of salicylazosulphapyridine in man
77. The polymorphic acetylation of sulphapyridine in man
78. Acetylation phenotype and adverse effects of sulphasalazine in healthy subjects
79. Inactivation of isoniazid in Burmese subjects
80. Acetylator phenotype in patients with hydralazine-induced lupoid syndrome
81. Pharmacokinetics in man of the N-acetylated metabolite of procainamide
82. Genetical and geographic studies on isoniazid inactivation
83. Studies on hydralazine I. Serum concentrations of hydralazine in man after a single dose and at steady state
84. Studies on hydralazine II. Elimination rate and steady state concentration in patients with impaired renal function
85. Comparison of the isoniazid inactivation in Finns and Lapps
86. A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis
87. The determination of the acetylator phenotype of tuberculosis patients in Czechoslovakia using sulphadimidine
88. Inaktivisering av medikamenter ved acetylering
89. Acetylating, deacetylating and amino acid conjugating enzymes
90. N-acetylation of drugs. Pharmacogenetic studies in rabbits selected for their acetylator characteristics
91. Relation of hydralazine plasma concentration to dosage and hypotensive action